|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 717.80 EUR | +1.01% |
|
+5.25% | +0.14% |
| 04-16 | Argenx's Vyvgart Seen Gaining More Patients in Coming Months, Wedbush Says | MT |
| 04-16 | European Equities Traded in the US as American Depositary Receipts Declining in Thursday Trading | MT |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 497M | 411M | 1.23B | 2.19B | 4.15B | |||||
Other Revenues, Total | 30.99M | 30.26M | 42.28M | 57.97M | 85.15M | |||||
Total Revenues | 528M | 441M | 1.27B | 2.25B | 4.24B | |||||
Cost of Goods Sold, Total | 581M | 693M | 977M | 1.21B | 1.81B | |||||
Gross Profit | -52.25M | -252M | 291M | 1.04B | 2.42B | |||||
Selling General & Admin Expenses, Total | 308M | 472M | 712M | 1.06B | 1.37B | |||||
Other Operating Expenses, Total | 308M | 472M | 712M | 1.06B | 1.37B | |||||
Operating Income | -360M | -724M | -421M | -17.84M | 1.05B | |||||
Interest Expense, Total | -412K | -1.34M | -693K | -2.07M | -3.18M | |||||
Interest And Investment Income | 3.49M | 24.74M | 92.96M | 139M | 163M | |||||
Net Interest Expenses | 3.08M | 23.4M | 92.27M | 137M | 160M | |||||
Income (Loss) On Equity Invest. | - | -677K | -4.41M | -7.64M | -12.39M | |||||
Currency Exchange Gains (Loss) | -50.05M | -32.73M | 14.07M | -48.21M | 65.79M | |||||
Other Non Operating Income (Expenses) | 10.47M | -852K | -211K | -392K | -907K | |||||
EBT, Excl. Unusual Items | -396M | -735M | -319M | 62.58M | 1.27B | |||||
Gain (Loss) On Sale Of Investments | -3.34M | 5.47M | 14.42M | 22.6M | 11.58M | |||||
EBT, Incl. Unusual Items | -400M | -729M | -304M | 85.18M | 1.28B | |||||
Income Tax Expense | 8.52M | -19.72M | -9.44M | -748M | -13.43M | |||||
Earnings From Continuing Operations | -408M | -710M | -295M | 833M | 1.29B | |||||
Net Income to Company | -408M | -710M | -295M | 833M | 1.29B | |||||
Net Income - (IS) | -408M | -710M | -295M | 833M | 1.29B | |||||
Net Income to Common Incl Extra Items | -408M | -710M | -295M | 833M | 1.29B | |||||
Net Income to Common Excl. Extra Items | -408M | -710M | -295M | 833M | 1.29B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -7.99 | -13.05 | -5.16 | 13.92 | 21.08 | |||||
Basic EPS - Continuing Operations | -7.99 | -13.05 | -5.16 | 13.92 | 21.08 | |||||
Basic Weighted Average Shares Outstanding | 51.08M | 54.38M | 57.17M | 59.86M | 61.3M | |||||
Net EPS - Diluted | -7.99 | -13.05 | -5.16 | 12.78 | 19.57 | |||||
Diluted EPS - Continuing Operations | -7.99 | -13.05 | -5.16 | 12.78 | 19.57 | |||||
Diluted Weighted Average Shares Outstanding | 51.08M | 54.38M | 57.17M | 65.18M | 66.03M | |||||
Normalized Basic EPS | -4.85 | -8.44 | -3.49 | 0.65 | 12.92 | |||||
Normalized Diluted EPS | -4.85 | -8.44 | -3.49 | 0.6 | 11.99 | |||||
American Depositary Receipts Ratio (ADR) | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | |||||
Supplemental Items | ||||||||||
EBITDA | -358M | -623M | -317M | -16.32M | 1.06B | |||||
EBITA | -360M | -625M | -319M | -17.84M | 1.06B | |||||
EBIT | -360M | -724M | -421M | -17.84M | 1.05B | |||||
EBITDAR | -358M | -622M | -315M | 4.56M | 1.08B | |||||
Total Revenues (As Reported) | 539M | 445M | 1.27B | 2.25B | 4.25B | |||||
Effective Tax Rate - (Ratio) | -2.13 | 2.7 | 3.1 | -877.98 | -1.05 | |||||
Total Current Taxes | 14.83M | 27.17M | 11.67M | 53.84M | 338M | |||||
Total Deferred Taxes | -6.3M | -46.89M | -21.12M | -802M | -351M | |||||
Normalized Net Income | -248M | -459M | -199M | 39.11M | 792M | |||||
Interest on Long-Term Debt | 1.1M | 2.19M | 904K | 2.46M | 4.08M | |||||
Non-Cash Pension Expense | 3.68M | 5.81M | 8.85M | 14.83M | 27.03M | |||||
Supplemental Operating Expense Items | ||||||||||
Marketing Expenses | - | - | - | 307M | 395M | |||||
Selling and Marketing Expenses | - | - | - | 307M | 395M | |||||
General and Administrative Expenses | - | - | - | - | - | |||||
Research And Development Expense From Footnotes | 581M | 663M | 859M | 983M | 1.36B | |||||
Net Rental Expense, Total | 219K | 753K | 1.56M | 20.89M | 16.04M | |||||
Imputed Operating Lease Interest Expense | 68.35K | 677K | 532K | 11.73M | 9.45M | |||||
Imputed Operating Lease Depreciation | 151K | 75.74K | 1.02M | 9.16M | 6.59M | |||||
Stock-Based Comp., Other (Total) | 179M | 157M | 233M | 235M | 248M | |||||
Total Stock-Based Compensation | 179M | 157M | 233M | 235M | 248M |
- Stock Market
- Equities
- ARGX Stock
- Financials argenx SE
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















